Zydus Lifesciences (NSEI:ZYDUSLIFE) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ZYDUSLIFE 주식 개요

Zydus Lifesciences Limited는 인도, 미국 및 국제적으로 의약품의 연구, 개발, 생산, 마케팅, 유통 및 판매에 종사하고 있습니다.

ZYDUSLIFE 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	5/6
재무 상태	6/6
배당금	4/6

보상

주가수익률( 31.4 x)이 Indian 시장( 34 x)보다 낮습니다.

지난 1년간 수익이 95.3% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

불안정한 배당 실적

Zydus Lifesciences Limited 경쟁사

Lupin

BSE:500257

₹1.0t

Torrent Pharmaceuticals

BSE:500420

₹1.2t

Dr. Reddy's Laboratories

BSE:500124

₹1.1t

Cipla

NSEI:CIPLA

₹1.4t

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Zydus Lifesciences
과거 주가
현재 주가	₹1,075.95
52주 최고치	₹1,324.30
52주 최저치	₹567.75
베타	0.46
11개월 변경	-4.61%
3개월 변경 사항	0.81%
1년 변경 사항	74.95%
33년 변화	93.62%
5년 변화	363.47%
IPO 이후 변화	12,300.62%

최근 뉴스 및 업데이트

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

주주 수익률

	ZYDUSLIFE	IN Pharmaceuticals	IN 마켓
7D	2.0%	1.5%	1.3%
1Y	75.0%	59.4%	45.4%

수익률 대 산업: ZYDUSLIFE 지난 1년 동안 51.1 %를 반환한 Indian Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: ZYDUSLIFE 지난 1년 동안 43.7 %를 반환한 Indian 시장을 초과했습니다.

가격 변동성

Is ZYDUSLIFE's price volatile compared to industry and market?
ZYDUSLIFE volatility
ZYDUSLIFE Average Weekly Movement	4.2%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	3.9%

안정적인 주가: ZYDUSLIFE 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ZYDUSLIFE 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1952	26,921	Sharvil Patel	zyduslife.com

자이더스 라이프사이언스는 인도, 미국 및 국제적으로 의약품의 연구, 개발, 생산, 마케팅, 유통 및 판매에 종사하는 회사입니다. 이 회사는 두 가지 부문으로 운영됩니다: 제약 및 소비자 제품입니다. 제네릭, 브랜드 제네릭, 바이오시밀러 및 백신을 포함한 특수 제제, 활성 의약품 성분, 소비자 웰빙 제품, 동물 헬스케어 제품, 통증 관리, 신경학, 대사 장애 및 간 질환 치료 분야의 제품 등 완제품 인체용 제제를 제공합니다.

Zydus Lifesciences Limited 기본 사항 요약

Zydus Lifesciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ZYDUSLIFE 기본 통계
시가총액	₹1.08t
수익(TTM)	₹41.69b
수익(TTM)	₹206.15b

26.0x

P/E 비율

5.3x

P/S 비율

ZYDUSLIFE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ZYDUSLIFE 손익 계산서(TTM)
수익	₹206.15b
수익 비용	₹63.05b
총 이익	₹143.10b
기타 비용	₹101.41b
수익	₹41.69b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	41.43
총 마진	69.41%
순이익 마진	20.22%
부채/자본 비율	3.7%

ZYDUSLIFE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

0.3%

현재 배당 수익률

8%

지급 비율

ZYDUSLIFE 주식 개요

보상

위험 분석

Zydus Lifesciences Limited 경쟁사

BSE:500257

₹1.0t

BSE:500420

₹1.2t

BSE:500124

₹1.1t

NSEI:CIPLA

₹1.4t

가격 내역 및 성능

최근 뉴스 및 업데이트

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024